Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Due to system maintenance, login and edit functionaility is currently unavailable

GM-CSF Priming with successive concomitant therapy with low-dose ARA-C for older patients with advanced myelodysplastic syndrome (MDS), secondary or refractory acute myeloid leukemia (AML)

GM-CSF Priming with successive concomitant therapy with low-dose ARA-C for older patients with advanced myelodysplastic syndrome (MDS), secondary or refractory acute myeloid leukemia (AML). Am Society of Hematology. 1998.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.